Loading...
•
Dec 31, 2021
Fulgent Q4 2021 Earnings Report
Fulgent Genetics' Q4 2021 earnings exceeded expectations, driven by strong core and COVID business performance.
Key Takeaways
Fulgent Genetics reported strong Q4 2021 results, with revenue of $251.7 million and core revenue growth of 234%. The company's GAAP income was $104.3 million, or $3.34 per share, and non-GAAP income was $108.7 million, or $3.48 per share.
Revenue totaled $251.7 million.
Billable tests delivered approximately 2.5 million.
Core Revenue grew 234% year-over-year to $40.1 million.
GAAP income was $104.3 million, or $3.34 per share.
Revenue by Segment
Forward Guidance
For the first quarter of 2022, Fulgent Genetics expects total revenue of approximately $245 million and core revenue including COVID-19 NGS of approximately $32 million, representing growth of 92% year-over-year.
Positive Outlook
- Total Revenue of approximately $245 million
- Core Revenue including COVID-19 NGS of approximately $32 million, representing growth of 92% year-over-year
- Core Revenue excluding COVID-19 NGS of approximately $22 million
- Total Revenue of approximately $600 million for full year 2022
- Core Revenue excluding COVID-19 NGS of approximately $120 million for full year 2022
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...